Literature DB >> 12706119

Characterisation and properties of ectosomes released by human polymorphonuclear neutrophils.

Olivier Gasser1, Christoph Hess, Sylvie Miot, Catherine Deon, Jean-Charles Sanchez, Jürg A Schifferli.   

Abstract

Human neutrophils release vesicles when activated in vitro and in vivo, in local and systemic inflammation. We have suggested that the presence of these vesicles is due to ectocytosis, defined as the release of rightside-out oriented vesicles expressing a select set of membrane proteins. Herein we have characterised the vesicles released by neutrophils to be ectosomes with specific properties. They contained cytosolic F-actin indicating their outside-out orientation. They bound Annexin V, suggesting that they expose phosphatidylserine, similarly to platelet microparticles. They expressed a subset of cell surface proteins (selectins and integrins, complement regulators, HLA-1, FcgammaRIII, and CD66b, but not CD14, FcgammaRII, and CD87). There was no specificity for transmembrane or glycosyl-phosphatidylinositol-linked proteins and, unexpectedly, L-selectin, known to be cleaved from the surface of activated neutrophils, was present. Ectosomes exposed active enzymes released by neutrophils upon degranulation (matrix metalloproteinase-9, myeloperoxidase, proteinase 3, and elastase). In particular, released myeloperoxidase was able to bind back to ectosomes. The purified complement protein C1q and C1q from serum bound to ectosomes as well. Another aspect of ectosomes was that they became specifically adherent to monocytic and endothelial cells. These observations suggest that neutrophil-derived ectosomes have unique characteristics that make them candidates for playing roles in inflammation and cell signaling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12706119     DOI: 10.1016/s0014-4827(03)00055-7

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  100 in total

Review 1.  Ectosomes as modulators of inflammation and immunity.

Authors:  S Sadallah; C Eken; J A Schifferli
Journal:  Clin Exp Immunol       Date:  2010-10-29       Impact factor: 4.330

Review 2.  Ectosomes as immunomodulators.

Authors:  Salima Sadallah; Ceylan Eken; Jürg A Schifferli
Journal:  Semin Immunopathol       Date:  2010-12-07       Impact factor: 9.623

Review 3.  Membrane vesicles as conveyors of immune responses.

Authors:  Clotilde Théry; Matias Ostrowski; Elodie Segura
Journal:  Nat Rev Immunol       Date:  2009-06-05       Impact factor: 53.106

Review 4.  Cell-cell communication via extracellular membrane vesicles and its role in the immune response.

Authors:  Inkyu Hwang
Journal:  Mol Cells       Date:  2013-06-25       Impact factor: 5.034

Review 5.  Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics.

Authors:  Mauro Perretti; Jesmond Dalli
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

Review 6.  Extracellular vesicles in renal disease.

Authors:  Diana Karpman; Anne-Lie Ståhl; Ida Arvidsson
Journal:  Nat Rev Nephrol       Date:  2017-07-24       Impact factor: 28.314

Review 7.  Microparticles and cardiovascular diseases.

Authors:  Christos Voukalis; Eduard Shantsila; Gregory Y H Lip
Journal:  Ann Med       Date:  2019-06-17       Impact factor: 4.709

8.  Purification of exosome-like vesicles from urine.

Authors:  Christopher Y Chen; Marie C Hogan; Christopher J Ward
Journal:  Methods Enzymol       Date:  2013       Impact factor: 1.600

9.  Human microparticles generated during sepsis in patients with critical illness are neutrophil-derived and modulate the immune response.

Authors:  Priya S Prakash; Charles C Caldwell; Alex B Lentsch; Timothy A Pritts; Bryce R H Robinson
Journal:  J Trauma Acute Care Surg       Date:  2012-08       Impact factor: 3.313

Review 10.  Cell-to-cell miRNA transfer: from body homeostasis to therapy.

Authors:  Roxana S Redis; Steliana Calin; Yaling Yang; M James You; George A Calin
Journal:  Pharmacol Ther       Date:  2012-08-08       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.